Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Editas Medicine Sector: Gene editing HQ: 11 Hurley St, Cambridge, MA Year Founded: 2013 Key Leaders: Gilmore O'Neill, President and CEO Number of Employees: Around 250 Stage: Public Financial Snapshot: $284.15 million market cap Notable Investors: The Vanguard Group, BlackRock, as well as early-stage investors that include Google Ventures and Bill Gates Key Products: Editas Medicines lead program, EDIT-101, is a CRISPR gene-editing therapy for Leber congenital amaurosis (LCA10)
V.et al (2015)
Its inclusion in the Lemon Bottle formula ensures the effective dissolution of fat, facilitating its removal from the body
This triple mechanism sets it apart from currently approved medicines such as semaglutide (a GLP-1R monoagonist) and tirzepatide (a GLP-1R/GIPR dual agonist)
:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)
US$ 25.39
US$ 22.52
US$ 20.78
US$ 20.75
US$ 21.45
